New research indicates that a greater number of women could benefit from targeted therapies for breast and ovarian cancer, following a landmark study that mapped mutations within tumours. Experts from the Manchester Cancer Research Centre and the Institute of Cancer Research have achieved a significant first, decoding the complete spectrum of mutations that drive tumour growth. This breakthrough is poised to usher in a new era of precision medicine, offering more effective treatments to thousands of individuals battling cancer.
The findings also present a potential key to understanding the recent rise in bowel cancer cases among younger adults. Over a six-year period, a dedicated team of scientists meticulously examined the genetic make-up of tumours across 16 distinct cancer types. Their comprehensive analysis involved processing an "enormous" volume of data, drawn from 10,983 cancer patients who participated in the 100,000 Genomes Project.
